VCB-1206

N/A

Report date: 2025/06/30 17:21:55

Base Information

Drug NameVCB-1206

Drug Alias NameVCB-1206

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionNatural killer cell replacementsB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsAutoimmune Diseases

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVaxcellBio Inc

China Registration ClassN/A

Develop Information

Active CompaniesVaxcellBio Inc

Inactive CompaniesN/A

Active IndicationsAutoimmune Diseases

Inactive IndicationsN/A

Other Information

ATC CodeN/A